<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>456-RILPIVIRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the rilpivirine</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>If necessary, use an H2 receptor antagonist in one dose per day, to be taken at least 12 hours before or at least 4 hours after.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>456-RILPIVIRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of rilpivirine by the proton pump inhibitor (decreased absorption because of increase of the gastric pH)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>456-RILPIVIRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>With the exception of dexamethasone administered in a single dose</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>456-RILPIVIRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>456-RILPIVIRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentratons of rilpivirine due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
